Voyant Bio creates a causal, functional spatial intelligence atlas of human anti‑tumor immunity by applying custom multiplex IHC panels with 20+ markers and proprietary AI analytics to primary human tumors. This platform reveals how immune‑cell organization—such as dendritic‑helper‑CD8 triads—affects response to immunotherapies, enabling rapid mechanistic insights, trial‑ready biomarker hypotheses, and more translatable drug development decisions.
Funding
Funding not disclosed
Founders
Product
Problem
Immune‑oncology (IO) drug decisions rely on in‑vitro assays and standard IHC panels that cannot capture the spatial organization of immune cells within human tumors, leading to poor translatability of preclinical findings and high clinical failure rates.
Solution
Voyant Bio builds a causal, functional spatial intelligence atlas of human anti‑tumor immunity by applying custom multiplex immunohistochemistry panels with more than 20 markers to primary human tumor samples. Proprietary AI analytics quantify the presence and modulation of organized immune triads—mature dendritic cells, CXCL13⁺ CD4⁺ helper T cells, and progenitor PD‑1⁺ CD8⁺ T cells—that drive response to therapies such as PD‑1 blockade. The platform delivers rapid mechanistic insights into how candidate IO agents create, restore, or disrupt these structures, enabling generation of trial‑ready biomarker hypotheses and mechanistic narratives. This approach aims to improve the predictability of human responses, reduce clinical failure risk, and support more informed decision‑making for immunotherapy development.
Target Audience
Primary customers are pharmaceutical and biotech companies developing immune‑oncology therapeutics, as well as contract research organizations that need high‑resolution spatial biomarker data to guide preclinical and clinical programs.
Features
- Custom multiplex IHC panels covering 20+ immune markers for high‑dimensional spatial profiling of human tumors
- Proprietary AI‑driven spatial intelligence analytics that detect and quantify functional immune triads
- Rapid generation of mechanistic insights linking candidate therapies to changes in immune cell organization
- Production of trial‑ready biomarker hypotheses for patient stratification and combination‑therapy design
- Intuitive, evidence‑backed mechanism‑of‑action narratives to support regulatory and investor communications